- Home
- HNVR vs NKTX Comparison
HNVR vs NKTX Comparison
Compare HNVR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- NKTX
- Stock Information
- Founded
- HNVR 2008
- NKTX 2015
- Country
- HNVR United States
- NKTX United States
- Employees
- HNVR N/A
- NKTX N/A
- Industry
- HNVR Commercial Banks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- NKTX Health Care
- Exchange
- HNVR Nasdaq
- NKTX Nasdaq
- Market Cap
- HNVR 143.6M
- NKTX 131.3M
- IPO Year
- HNVR 2022
- NKTX 2020
- Fundamental
- Price
- HNVR $23.47
- NKTX $1.95
- Analyst Decision
- HNVR Buy
- NKTX Strong Buy
- Analyst Count
- HNVR 1
- NKTX 6
- Target Price
- HNVR $22.00
- NKTX $15.00
- AVG Volume (30 Days)
- HNVR 26.0K
- NKTX 675.7K
- Earning Date
- HNVR 04-23-2025
- NKTX 05-20-2025
- Dividend Yield
- HNVR 1.69%
- NKTX N/A
- EPS Growth
- HNVR N/A
- NKTX N/A
- EPS
- HNVR 1.30
- NKTX N/A
- Revenue
- HNVR $65,041,000.00
- NKTX N/A
- Revenue This Year
- HNVR N/A
- NKTX N/A
- Revenue Next Year
- HNVR $15.80
- NKTX N/A
- P/E Ratio
- HNVR $18.21
- NKTX N/A
- Revenue Growth
- HNVR 1.13
- NKTX N/A
- 52 Week Low
- HNVR $15.92
- NKTX $1.31
- 52 Week High
- HNVR $27.14
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- HNVR 60.51
- NKTX 51.98
- Support Level
- HNVR $22.37
- NKTX $1.81
- Resistance Level
- HNVR $23.80
- NKTX $2.16
- Average True Range (ATR)
- HNVR 0.75
- NKTX 0.16
- MACD
- HNVR 0.15
- NKTX -0.02
- Stochastic Oscillator
- HNVR 86.60
- NKTX 34.00
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.